Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MARS1 | P56192 | 14/20 | 1.00 |
| ▸ | SLC16A3 | O15427 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | TACR3 | P29371 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL117660 | 0.83 | MARS1 (1.00) | MARS1NPC1 | |
| SCHEMBL117499 | 0.82 | MARS1 (1.00) | MARS1SLC16A3 | |
| SCHEMBL117500 | 0.81 | MARS1 (1.00) | MARS1SLC16A3 | |
| SCHEMBL27687135 | 0.76 | MARS1 (0.65) | MARS1CYP1A2CYP2C9 | |
| SCHEMBL8367181 | 0.76 | MARS1 (0.65) | MARS1SLC16A3CYP1A2CYP3A4CYP2C9 | |
| Hydrochloric Acid SCHEMBL8364783 | 0.74 | MARS1 (0.64) | MARS1SLC16A3CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL117516 | 0.72 | SMN1; SMN2 (0.60) | MARS1CYP1A2CYP2C9 | |
| SCHEMBL27687138 | 0.71 | SMN1; SMN2 (0.69) | MARS1CYP1A2CYP2C9 | |
| SCHEMBL3436589 | 0.70 | MARS1 (0.58) | MARS1NPC1 | |
| SCHEMBL27706388 | 0.69 | GRN (0.56) | MARS1CYP1A2CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120058133-A1 | INHIBITION OF TRNA SYNTHETASES AND THERAPEUTIC APPLICATIONS THEREOF | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2012-03-08 | — | — | US | disclosed |
| US-20120058133-A1 | INHIBITION OF TRNA SYNTHETASES AND THERAPEUTIC APPLICATIONS THEREOF | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2012-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120058133-A1 | INHIBITION OF TRNA SYNTHETASES AND THERAPEUTIC APPLICATIONS THEREOF | AARS1, GARS1, TRMT1 | MARS1 55/4885SLC16A3 3951/4885CYP1A2 4312/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.